Yi Shen Juan Bi Pill Regulates the Bone Immune Microenvironment via the JAK2/STAT3 Signaling Pathway in Vitro

被引:10
|
作者
Xia, Ya [1 ]
Fan, Danping [2 ,3 ,4 ]
Li, Xiaoya [5 ]
Lu, Xiangchen [1 ,4 ,6 ]
Ye, Qinbin [4 ]
Xi, Xiaoyu [4 ]
Wang, Qiong [4 ]
Zhao, Hongyan [7 ]
Xiao, Cheng [2 ,3 ,4 ]
机构
[1] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Plant Dev, Beijing, Peoples R China
[6] Beijing Tradit Chinese Med Hosp, Pinggu Hosp, Beijing, Peoples R China
[7] China Acad Chinese Med Sci, Beijing Key Lab Res Chinese Med Prevent & Treatme, Expt Res Ctr, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
rheumatoid arthritis; Yi Shen Juan Bi Pill; osteoclast; regulatory T cell; JAK2; STAT3 signaling pathway; AUTOIMMUNE ARTHRITIS; T-CELLS; OSTEOIMMUNOLOGY; TRANSCRIPTION; ADALIMUMAB; ACTIVATION; MECHANISMS; PLACEBO;
D O I
10.3389/fphar.2021.746786
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rheumatoid arthritis (RA) is characterized by an impaired articular bone immune microenvironment, which is associated with regulatory T cells (Tregs) hypofunction and osteoclasts (OCs) hyperfunction and leads to articular bone erosion and systemic bone loss. Studies have shown that Tregs slow bone loss in RA by regulating the bone resorption function of OCs and the JAK/STAT signaling pathway can regulate the immunosuppressive function of Tregs and reduce the bone erosion function of OCs. Yi Shen Juan Bi Pill (YSJB) is a classic Chinese herbal compound for the treatment of RA. However, whether YSJB regulates bone immune microenvironment homeostasis through JAK/STAT signaling pathway remains unclear. Based on in vitro OC single culture, Treg single culture and OC-Treg coculture systems, treatments were performed using drug-containing serum, AG490 and JAK2 siRNA to explore whether YSJB-containing serum regulates the homeostasis of the bone immune microenvironment through the JAK/STAT signaling pathway. In vitro, YSJB treatment decreased the number of TRAP(+) cells and the areas of bone resorption and inhibited the expression of RANK, NFATc1, c-fos, JAK2, and STAT3 in both the OC single culture system and the OC-Treg coculture system. Tregs further reduced the number of TRAP(+) cells and the areas of bone resorption in the coculture system. YSJB promoted the secretion of IL-10 while inhibiting the expression of JAK2 and STAT3 in Tregs. Moreover, inhibiting the expression of JAK2 with the JAK2 inhibitor AG490 and JAK2 siRNA improved the immunosuppressive functions of Treg, inhibited OC differentiation and bone resorption. Our study demonstrates that YSJB can regulate OC-mediated bone resorption and Treg-mediated bone immunity through the JAK2/STAT3 signaling pathway. This study provides a new strategy for regulating the bone immune microenvironment in RA with traditional Chinese medicine.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Correlation of IL-6 and JAK2/STAT3 signaling pathway with prognosis of nasopharyngeal carcinoma patients
    Zhuang, Mengqi
    Ding, Xiaotong
    Song, Wenli
    Chen, Huimin
    Guan, Hui
    Yu, Yang
    Zhang, Zicheng
    Dong, Xinzhe
    AGING-US, 2021, 13 (12): : 16667 - 16683
  • [42] Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway
    Jia, Fei
    Liu, Yu
    Dou, Xinyu
    Du, Chuanchao
    Mao, Tianli
    Liu, Xiaoguang
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [43] Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway
    Ruan, Hao
    Luan, Jiaoyan
    Gao, Shaoyan
    Li, Shuangling
    Jiang, Qiuyan
    Liu, Rui
    Liang, Qing
    Zhang, Ruiqin
    Zhang, Fangxia
    Li, Xiaohe
    Zhou, Honggang
    Yang, Cheng
    MOLECULES, 2021, 26 (15):
  • [44] Effect of the JAK2/STAT3 signaling pathway on nerve cell apoptosis in rats with white matter injury
    Chen, X-M
    Yu, Y-H
    Wang, L.
    Zhao, X-Y
    Li, J-R
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (01) : 321 - 327
  • [45] In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
    Severin, Filippo
    Frezzato, Federica
    Visentin, Andrea
    Martini, Veronica
    Trimarco, Valentina
    Carraro, Samuela
    Tibaldi, Elena
    Brunati, Anna Maria
    Piazza, Francesco
    Semenzato, Gianpietro
    Facco, Monica
    Trentin, Livio
    CANCERS, 2019, 11 (12)
  • [46] Human nail bed extracellular matrix facilitates bone regeneration via macrophage polarization mediated by the JAK2/STAT3 pathway
    Yu, Yaling
    Cui, Haomin
    Zhang, Cheng
    Zhang, Demin
    Yin, Jun
    Wen, Gen
    Chai, Yimin
    JOURNAL OF MATERIALS CHEMISTRY B, 2020, 8 (18) : 4067 - 4079
  • [47] ISG15 promotes tumor progression via IL6/JAK2/STAT3 signaling pathway in ccRCC
    Xie, Wei
    Zhang, Yuanfeng
    Zhang, Zhechuan
    Li, Qinke
    Tao, Lesha
    Zhang, Ronggui
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [48] Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway
    Fang, Xiuli
    Liu, Yajun
    Lu, Jing
    Hong, Huiqi
    Yuan, Jing
    Zhang, Yuhong
    Wang, Panxia
    Liu, Peiqing
    Ye, Jiantao
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 (12) : 1373 - 1385
  • [49] Rhein Protects Against Severe Acute Pancreatitis In vitro and In vivo by Regulating the JAK2/STAT3 Pathway
    Yang, Xiaofang
    Geng, Huan
    You, Lijiao
    Yuan, Lin
    Meng, Jialei
    Ma, Yuhui
    Gu, Xuelian
    Lei, Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
    Long, Lin
    Fei, Xiangyu
    Chen, Liucui
    Yao, Liang
    Lei, Xiaoyong
    FRONTIERS IN ONCOLOGY, 2024, 14